Liquidia Corporation (NASDAQ:LQDA) Receives Average Rating of “Hold” from Brokerages

Liquidia Corporation (NASDAQ:LQDA) has received an average rating of “Hold” from the twelve ratings firms that are covering the company, MarketBeat reports. Two analysts have rated the stock with a sell rating, six have given a hold rating, three have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $83.69.

Several analysts have weighed in on the company. Royal Bank Of Canada set a $130.00 target price on Liquidia in a research note on Friday, July 24th. Stephens set a $130.00 price target on Liquidia in a research note on Friday, July 24th. Lifesci Capital lowered Liquidia from an “outperform” rating to a “hold” rating and set a $90.00 price target on the stock. in a report on Wednesday, August 12th. Raymond James Financial cut shares of Liquidia from a “strong-buy” rating to an “outperform” rating and cut their price objective for the company from $106.00 to $53.00 in a research note on Thursday. Finally, BTIG Research downgraded shares of Liquidia from a “buy” rating to a “neutral” rating in a report on Thursday.

Liquidia Price Performance

NASDAQ LQDA opened at $28.64 on Monday. The company has a 50-day moving average price of $71.62 and a two-hundred day moving average price of $62.21. Liquidia has a 52 week low of $21.91 and a 52 week high of $93.61. The stock has a market cap of $2.56 billion, a price-to-earnings ratio of 20.91 and a beta of 0.61. The company has a current ratio of 2.31, a quick ratio of 2.12 and a debt-to-equity ratio of 0.63.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). Liquidia had a net margin of 30.74% and a return on equity of 149.65%. The business had revenue of $171.68 million for the quarter, compared to the consensus estimate of $168.48 million. During the same period last year, the firm posted ($0.49) EPS. The business’s quarterly revenue was up 1842.1% on a year-over-year basis. Analysts forecast that Liquidia will post 2.34 EPS for the current year.

Liquidia News Roundup

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia’s legal options are not exhausted: an appeal could potentially overturn or narrow the ruling, giving investors a possible path to recovery if Yutrepia’s market opportunity is preserved. Liquidia Stock Crashed 57% in a Day After a Delaware Court Ruling
• Positive Sentiment: Despite the litigation setback, Jefferies upgraded LQDA to “strong buy,” while HC Wainwright maintained a “buy” rating and set a $58 price target. These calls indicate that some analysts believe the selloff has overstated the long-term damage or that an appeal could succeed.
• Neutral Sentiment: HC Wainwright cut its target from $130 to $58, and Needham reduced its target from $110 to $72, although both retained “buy” ratings. The sharply lower targets reflect materially higher legal and commercialization risk even among bullish analysts.
• Negative Sentiment: BTIG downgraded Liquidia to “neutral,” and Wells Fargo added to the analyst downgrades following the patent ruling. Analysts cited uncertainty over Yutrepia’s PH-ILD indication and the possibility that UTHR’s patent victory could limit Liquidia’s addressable market. Liquidia extends losses as Wells Fargo adds to downgrades
• Negative Sentiment: The court setback triggered a severe selloff, leaving LQDA on track for its worst week on record as investors reassessed Yutrepia’s revenue potential and Liquidia’s competitive position. The stock’s unusually heavy trading volume underscores the market’s heightened uncertainty. LQDA Stock On Track For Worst Week Ever

Insider Activity at Liquidia

In other news, CAO Dana Boyle sold 1,600 shares of the stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $87.53, for a total value of $140,048.00. Following the completion of the transaction, the chief accounting officer directly owned 167,919 shares in the company, valued at $14,697,950.07. This trade represents a 0.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Raman Singh sold 8,468 shares of the firm’s stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $66.16, for a total transaction of $560,242.88. Following the transaction, the director owned 44,637 shares in the company, valued at $2,953,183.92. This represents a 15.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 572,519 shares of company stock worth $44,087,514 in the last three months. Insiders own 25.60% of the company’s stock.

Institutional Investors Weigh In On Liquidia

Several hedge funds and other institutional investors have recently added to or reduced their stakes in LQDA. Bank of New York Mellon Corp acquired a new stake in Liquidia during the second quarter valued at approximately $29,694,000. Bank of America Corp DE grew its position in Liquidia by 18.7% in the first quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock worth $86,341,000 after buying an additional 360,372 shares during the last quarter. Capricorn Fund Managers Ltd acquired a new position in Liquidia in the first quarter worth approximately $9,337,000. T3 Companies LLC bought a new position in shares of Liquidia in the fourth quarter valued at $6,084,000. Finally, Eversept Partners LP increased its holdings in shares of Liquidia by 33.0% in the first quarter. Eversept Partners LP now owns 677,392 shares of the company’s stock valued at $25,565,000 after buying an additional 167,949 shares in the last quarter. Institutional investors own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).